Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

Tonsillectomy Clinical Trial

Official title:

Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02829164
• Other study ID #: 6402
• Status: Recruiting
• Phase: N/A
• First received: June 16, 2016
• Last updated: May 19, 2017
• Start date: April 2016
• Est. completion date: September 2017

Study information

• Verified date: May 2017
• Source: University Hospital, Strasbourg, France
• Contact: Laetitia HIGEL, MD
• Phone: 33 (0)3.88.12.77.40
• Email: laetitia.higel[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described in 10 to 30 % of cases in Berger's disease and in 15 to 20% of cases in nephropathy HSP. These two pathological entities share biological and histological characteristics, as well as common pathophysiological mechanisms, particularly the production of abnormally glycosylated IgA1 promoting their proliferation in the mesangium. Tonsils part of Iga abnormal production sites that would be associated with an infectious stimulus, tonsillectomy has been studied as a possible treatment in primitive IgA nephropathy. The benefit of tonsillectomy is controversial: many Japanese studies demonstrate its effectiveness in terms of reduction of proteinuria, improved renal function in the long term regression of histological lesions and reduced risk of relapse following clinical remission whereas European studies do not suggest its effectiveness in treating IgA nephropathy. In this context, the aim of our study is to describe the scope of practice of tonsillectomy in the treatment of primary renal disease in IgA child in the inter East region and describe the short renal become Strasbourg end of the cohort that received this treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion criteria:

• Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy

• Follow the University Hospital of Strasbourg since 2009

• Having received a tonsillectomy in their care

• Children whose holders of parental authority does not oppose the use of clinical data from their child for research purposes

Exclusion criteria:

• Children whose holders of parental authority are opposed to the use of clinical data from their child for research purposes

Related Conditions & MeSH terms

• Glomerulonephritis, IGA
• Kidney Diseases
• Tonsillectomy

Locations

Country	Name	City	State
France	Service de Pédiatrie 1 Hôpital de Hautepierre	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the management of the tonsillectomy at the CHU of Strasbourg by a standardized questionnaire		since January 2009